Learn about the economic and operational advantages of Single-Use Bioreactors (SUBs) for large-scale upstream bioprocessing. In this comparative analysis, the authors review the contribution of bioreactors to manufacturing footprints, associated production time lines and efficiencies, and true cost of goods for the production of biologics. They illustrate how 2,000-L and 5,000-L SUBs, like the 5,000-L HyPerformaDynaDrive SUB, may offer a level of volume efficiency, flexibility, and cost effectiveness not easily found with manufacturing strategies built around 15,000-L SS bioreactors.
Complete this form to read about the details in this white paper, entitled“Updating the Economics of Biologics Manufacturing with 5,000-L Single-Use Bioreactors, A Paradigm Shift” authored by Mark Thomas Smith, Levi Morin Larsen, Kevin M. Mullen, and Jeffrey Johnson.
